

08/436,339



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
---------------	-------------	-----------------------	---------------------

08/436,339 07/13/95 PAPAYANNOPOULOU

T B173-CIP
EXAMINER

JAMES F HALEY JR
FISH & NEAVE
1251 AVENUE OF THE AMERICAS
NEW YORK NY 10020

18M1/1209

JOHNSON, N PAPER NUMBER

1806

DATE MAILED: 12/09/97

NOTICE OF ALLOWABILITY

PART I.

- This communication is responsive to 8.26.97
- All the claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice Of Allowance And Issue Fee Due or other appropriate communication will be sent in due course.
- The allowed claims are 1-14
- The drawings filed on _____ are acceptable.
- Acknowledgment is made of the claim for priority under 35 U.S.C. 119. The certified copy has [...] been received. [...] not been received. [...] been filed in parent application Serial No. _____ filed on _____
- Note the attached Examiner's Amendment.
- Note the attached Examiner Interview Summary Record, PTOL-413.
- Note the attached Examiner's Statement of Reasons for Allowance.
- Note the attached NOTICE OF REFERENCES CITED, PTO-892.
- Note the attached INFORMATION DISCLOSURE CITATION, PTO-1449.

PART II.

A SHORTENED STATUTORY PERIOD FOR RESPONSE to comply with the requirements noted below is set to EXPIRE THREE MONTHS FROM THE "DATE MAILED" indicated on this form. Failure to timely comply will result in the ABANDONMENT of this application. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL APPLICATION, PTO-152, which discloses that the oath or declaration is deficient. A SUBSTITUTE OATH OR DECLARATION IS REQUIRED.
- APPLICANT MUST MAKE THE DRAWING CHANGES INDICATED BELOW IN THE MANNER SET FORTH ON THE REVERSE SIDE OF THIS PAPER.
 - Drawing informalities are indicated on the NOTICE RE PATENT DRAWINGS, PTO-948, attached hereto or to Paper No. Y. CORRECTION IS REQUIRED.
 - The proposed drawing correction filed on _____ has been approved by the examiner. CORRECTION IS REQUIRED.
 - Approved drawing corrections are described by the examiner in the attached EXAMINER'S AMENDMENT. CORRECTION IS REQUIRED.
 - Formal drawings are now REQUIRED.

Any response to this letter should include in the upper right hand corner, the following information from the NOTICE OF ALLOWANCE AND ISSUE FEE DUE: ISSUE BATCH NUMBER, DATE OF THE NOTICE OF ALLOWANCE, AND SERIAL NUMBER.

Attachments:

- Examiner's Amendment
- Examiner Interview Summary Record, PTOL- 413
- Reasons for Allowance
- Notice of References Cited, PTO-892
- Information Disclosure Citation, PTO-1449

- Notice of Informal Application, PTO-152
- Notice re Patent Drawings, PTO-948
- Listing of Bonded Draftsmen
- Other

JONI R. SCHEINER
PRIMARY EXAMINER
G-173 (CIP)

Serial Number: 08/436,339

#5/B

Art Unit: 1806

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CAR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee. Authorization for this examiner's amendment was given in a telephone interview with Kerry Flynn on 12/03/97.

2. The application has been amended as follows:

✓ On p.1, line 1 of the specification --This application is a national stage application under U.S.C. 371 of PCT/US93/11060, filed 11/15/93, which is a continuation-in-part of 07/977,702, filed 11/13/92, now abandoned. -- was inserted.

-On p. 11 of the specification -(SEQ ID NO:3)--, -(SEQ ID NO:4)--, -(SEQ ID NO:5)-- and --(SEQ ID NO:6)-- were inserted at the end of the description for each of Figures 7A, 7B, 8A and 8B, respectively.

-Non-elected claims 15-28 were canceled.

-In claim 1, line 2 "steps" was changed to --step--.

-In claim 2, line 3 --a mouse/human-- was inserted before "chimeric".

-In claim 2, line 4 "fibronectin, fibronectin having alternatively spliced non-type III connected segment, fibronectin peptides containing the amino acid sequence EILDV or a similar conservatively substituted amino acid sequence that blocks VLA-4 mediated adhesion, soluble VCAM-1, bifunctional VCAM-1/Ig fusion proteins and VCAM-1 peptides" was deleted.

B

Serial Number: 08/436,339

Art Unit: 1806

-In claim 4, line 2 "cytokine or 5-fluorouracil as a" was deleted.

b1 -In claim 4, line 2 after "in vivo" --, said stimulating agent being 5-fluorouracil or a cytokine that stimulates hematopoietic cells to proliferated-- was inserted.

b2 -In claim 5, line 2 "cytokine or 5-fluorouracil as a" was deleted.

b2 -In claim 5, line 2 after "in vivo" --, said stimulating agent being 5-fluorouracil or a cytokine that stimulates hematopoietic cells to proliferated-- was inserted.

b3 -In claim 6, line 2 "cytokine or 5-fluorouracil as a" was deleted.

b3 -In claim 6, line 2 after "in vivo" --, said stimulating agent being 5-fluorouracil or a cytokine that stimulates hematopoietic cells to proliferated-- was inserted.

b4 -In claim 7, line 2 --by-- was inserted after "mediated".

b4 -In claim 8 "G-CSF, stem cell factor, GM-CSF, M-CSF, T-SCF, SCPF, IL-1, IL-2, IL-3, IL-4, IL-6 and IL-11" was replaced with --granulocyte colony-stimulating factor (G-CSF), stem cell factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), totipotent stem cell factor (T-SCF), stem cell proliferation factor (SCPF), interleukin-1 (IL-1), interleukin-2 (IL-2), interleukin-3 (IL-3), interleukin-4 (IL-4), interleukin-6 (IL-6) and interleukin-11 (IL-11)--

b5 -In claim 9 "G-CSF, stem cell factor, GM-CSF, M-CSF, T-SCF, SCPF, IL-1, IL-2, IL-3, IL-4, IL-6 and IL-11" was replaced with --granulocyte colony-stimulating factor (G-CSF), stem cell factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), totipotent stem cell factor (T-SCF), stem cell proliferation factor

Serial Number: 08/436,339

BS
wrcd
Art Unit: 1806

(SCPF), interleukin-1 (IL-1), interleukin-2 (IL-2), interleukin-3 (IL-3), interleukin-4 (IL-4),
interleukin-6 (IL-6) and interleukin-11 (IL-11)

3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nancy Johnson whose telephone number is (703) 305-5860.

Toni R. Scheiner

TONI R. SCHEINER
PRIMARY EXAMINER
GROUP 1800

N. Johnson

NAJ

December 3, 1997

52



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

NOTICE OF ALLOWANCE AND ISSUE FEE DUE

18M1/1209

JAMES F HALEY JR
FISH & NEAVE
1251 AVENUE OF THE AMERICAS
NEW YORK NY 10020

APPLICATION NO. 60/188,520	FILING DATE 11/17/98	TOTAL CLAIMS 11	TO/IN/EXAMINER AND GROUP ART UNIT TO/IN/THALIA	1804	DATE MAILED 12/17/98
PAPAYANNOPOULOU, THALIA					
First Named Applicant PERIPHERALIZATION OF HEMATOPOIETIC STEM CELLS					
TITLE OF INVENTION					
ATTY'S DOCKET NO. 12110	CLASS-SUBCLASS 12110	BATCH NO. 111	APPLN. TYPE T	SMALL ENTITY <input checked="" type="checkbox"/>	FEES DUE 0
DATE DUE 12/17/98					

**THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT.
PROSECUTION ON THE MERITS IS CLOSED.**

**THE ISSUE FEE MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS
APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED.**

HOW TO RESPOND TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

- A. If the status is changed, pay twice the amount of the FEE DUE shown above and notify the Patent and Trademark Office of the change in status, or
- B. If the status is the same, pay the FEE DUE shown above.

If the SMALL ENTITY is shown as NO:

- A. Pay FEE DUE shown above, or
- B. File verified statement of Small Entity Status before, or with, payment of 1/2 the FEE DUE shown above.

II. Part B-Issue Fee Transmittal should be completed and returned to the Patent and Trademark Office (PTO) with your ISSUE FEE. Even if the ISSUE FEE has already been paid by charge to deposit account, Part B Issue Fee Transmittal should be completed and returned. If you are charging the ISSUE FEE to your deposit account, section "4b" of Part B-Issue Fee Transmittal should be completed and an extra copy of the form should be submitted.

III. All communications regarding this application must give application number and batch number.

Please direct all communications prior to issuance to Box ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.